M. Arnold, Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory, European Journal of Cancer, vol.51, issue.9, pp.1164-87, 1990.
DOI : 10.1016/j.ejca.2013.09.002

R. Kenneth and . Hess, Metastatic Patterns in Adenocarcinoma, pp.1624-1657, 2006.

L. Shenhong and . Wu, Routine Interval Computed Tomography to Detect New Soft-Tissue Disease Might Be Unnecessary in Patients with Androgen-Independent Prostate Cancer and Metastasis Only to Bone, BJU International, vol.99, issue.3, pp.525-553, 2007.

H. Pilge, Diagnostics and therapy of spinal metastases, Der Orthop??de, vol.2, issue.2, pp.185-193, 2011.
DOI : 10.1038/ncpneuro0116

R. Brook, R. Tung, and . Oeppen, Batson's Plexus and Retrograde Venous Spread of Malignancy ? a Pictorial Review, Cancer Imaging, vol.14, issue.19, p.40, 2014.

F. Arguello, Pathogenesis of vertebral metastasis and epidural spinal cord compression, Cancer, vol.14, issue.1, pp.98-106, 1990.
DOI : 10.1148/radiology.145.1.7122863

D. Singh, Is there a favorable subset of patients with prostate cancer who develop oligometastases?, International Journal of Radiation Oncology*Biology*Physics, vol.58, issue.1, pp.3-10, 2004.
DOI : 10.1016/S0360-3016(03)01442-1

M. Nørgaard, Skeletal Related Events, Bone Metastasis and Survival of Prostate Cancer: A Population Based Cohort Study in Denmark (1999 to 2007), The Journal of Urology, vol.184, issue.1, pp.162-67, 1999.
DOI : 10.1016/j.juro.2010.03.034

V. Molinié, Le score de Gleason en 2008, Annales de Pathologie, vol.28, issue.5, pp.350-53, 2008.
DOI : 10.1016/j.annpat.2008.07.006

J. I. Epstein, The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma, The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma, pp.1228-1270, 2005.
DOI : 10.1097/01.pas.0000173646.99337.b1

J. I. Epstein, The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma, The American Journal of Surgical Pathology, vol.40, issue.2, pp.244-52, 2016.
DOI : 10.1097/PAS.0000000000000530

V. Molinié, . M. Gleason-'s-score, and . Siddiqui, Le score de Gleason en 2008, Annales de Pathologie, vol.28, issue.5, pp.350-53, 1998.
DOI : 10.1016/j.annpat.2008.07.006

K. H. Zhao, External Validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment Score, Urology, vol.72, issue.2, pp.396-400, 2008.
DOI : 10.1016/j.urology.2007.11.165

N. Mottet, EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent, European Urology, vol.71, issue.4, pp.618-647, 2017.
DOI : 10.1016/j.eururo.2016.08.003

N. Mottet, EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent, European Urology, vol.71, issue.4, pp.618-647, 2017.
DOI : 10.1016/j.eururo.2016.08.003

P. Cornford, EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer, European Urology, vol.71, issue.4
DOI : 10.1016/j.eururo.2016.08.002

V. Ficarra, Systematic Review and Meta-analysis of Studies Reporting Urinary Continence Recovery After Robot-assisted Radical Prostatectomy, European Urology, vol.62, issue.3
DOI : 10.1016/j.eururo.2012.05.045

E. Haglind, Urinary Incontinence and Erectile Dysfunction After Robotic Versus Open Radical Prostatectomy: A Prospective, Controlled, Nonrandomised Trial, European Urology, vol.68, issue.2, pp.216-241, 2015.
DOI : 10.1016/j.eururo.2015.02.029

W. D. Heemsbergen, Long-term results of the Dutch randomized prostate cancer trial: Impact of dose-escalation on local, biochemical, clinical failure, and survival, Radiotherapy and Oncology, vol.110, issue.1
DOI : 10.1016/j.radonc.2013.09.026

A. Kalbasi, Dose-Escalated Irradiation and Overall Survival in Men With Nonmetastatic Prostate Cancer, JAMA Oncology, vol.1, issue.7, pp.897-906, 2015.
DOI : 10.1001/jamaoncol.2015.2316

J. D. Christopher and . Wallis, Second Malignancies after Radiotherapy for Prostate Cancer: Systematic Review and Meta-Analysis, BMJ, vol.352, issue.2, 2016.

R. Golan, Partial Gland Treatment of Prostate Cancer Using High-Intensity Focused Ultrasound in the Primary and Salvage Settings: A Systematic Review, The Journal of Urology, vol.198, issue.5, 2017.
DOI : 10.1016/j.juro.2017.03.137

C. R. Ramsay, Funding, Health Technology Assessment, vol.19, issue.49, pp.1-490, 2015.
DOI : 10.3310/hta19490

C. Huggins and C. V. Hodges, Studies on Prostatic Cancer: I. The Effect of Castration, Of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate, CA: A Cancer Journal for Clinicians, vol.22, issue.4, pp.232-272, 1972.
DOI : 10.3322/canjclin.22.4.232

F. Kunath, Non-Steroidal Antiandrogen Monotherapy Compared with Luteinising Hormone-Releasing Hormone Agonists or Surgical Castration Monotherapy for Advanced Prostate Cancer', The Cochrane Database of Systematic Reviews, 2014.

H. Akaza, Combined androgen blockade with bicalutamide for advanced prostate cancer, Cancer, vol.174, issue.15, pp.3437-3482, 2009.
DOI : 10.1002/cncr.24395

C. Schulman, Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND), European Urology, vol.69, issue.4, pp.720-747, 2016.
DOI : 10.1016/j.eururo.2015.10.007

S. Magnan, Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer, JAMA Oncology, vol.1, issue.9, pp.1261-69, 2015.
DOI : 10.1001/jamaoncol.2015.2895

G. Gravis, Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial, European Urology, vol.70, issue.2, pp.256-62, 2016.
DOI : 10.1016/j.eururo.2015.11.005

E. Scott, Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer, Urologic Oncology, vol.35, issue.123, 2017.

T. Milecki, The Use of Luteinizing Hormone-Releasing Hormone Analogues Is Still an Indispensable Element of Therapy in Castrate-Resistant Prostate Cancer, Contemporary Oncology, vol.18, issue.2, pp.85-89, 2014.

D. Taylor, D. Elson, and . Trump, Importance of continued testicular suppression in hormone-refractory prostate cancer., Journal of Clinical Oncology, vol.11, issue.11, pp.2167-72, 1993.
DOI : 10.1200/JCO.1993.11.11.2167

M. Stanbrough, Increased Expression of Genes Converting Adrenal Androgens to Testosterone in Androgen-Independent Prostate Cancer, Cancer Research, vol.66, issue.5
DOI : 10.1158/0008-5472.CAN-05-4000

J. Holzbeierlein, Gene Expression Analysis of Human Prostate Carcinoma during Hormonal Therapy Identifies Androgen-Responsive Genes and Mechanisms of Therapy Resistance, The American Journal of Pathology, vol.164, issue.1, pp.217-244, 2004.
DOI : 10.1016/S0002-9440(10)63112-4

G. Buchanan, Contribution of the androgen receptor to prostate cancer predisposition and progression, Cancer Metastasis Reviews, vol.20, issue.3, pp.4-207, 2001.
DOI : 10.1007/0-306-48143-X_6

C. Parker, Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer, New England Journal of Medicine, vol.369, issue.3, pp.213-2310, 2013.
DOI : 10.1056/NEJMoa1213755

. Saad, Radium-223 and Concomitant Therapies in Patients with Metastatic Castration- Resistant Prostate Cancer

E. Anassi and U. Ndefo, Sipuleucel-T (Provenge) Injection', Pharmacy and Therapeutics, pp.197-202, 2011.

P. Grimm, Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group, BJU International, vol.181, issue.1, pp.22-29, 2012.
DOI : 10.1016/j.juro.2008.09.027

T. J. Wilt, Follow-up of Prostatectomy versus Observation for Early Prostate Cancer, New England Journal of Medicine, vol.377, issue.2, pp.132-4210, 2017.
DOI : 10.1056/NEJMoa1615869

P. Léon, Prevalence and diversity of management of prostate cancer patients classified as low risk using D'Amico group or Cancer of the Prostate Risk Assessment (CAPRA) score: A French multicenter study]', Progres En Urologie: Journal De l'Association Francaise D'urologie Et De La Societe Francaise D'urologie 27, pp.158-65, 2017.

A. Briganti, Updated Nomogram Predicting Lymph Node Invasion in Patients with Prostate Cancer Undergoing Extended Pelvic Lymph Node Dissection: The Essential Importance of Percentage of Positive Cores, European Urology, vol.61, issue.3, pp.480-87, 2012.
DOI : 10.1016/j.eururo.2011.10.044

O. Yossepowitch, Secondary Therapy, Metastatic Progression, and Cancer-Specific Mortality in Men with Clinically High-Risk Prostate Cancer Treated with Radical Prostatectomy, European Urology, vol.53, issue.5, pp.950-59, 2008.
DOI : 10.1016/j.eururo.2007.10.008

V. D. Anthony and . Amico, Prostate Specific Antigen Doubling Time as a Surrogate End Point for Prostate Cancer Specific Mortality Following Radical Prostatectomy or Radiation Therapy, The Journal of Urology, vol.172, issue.5 2, pp.42-46, 2004.

J. A. Brockman, Nomogram Predicting Prostate Cancer???specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy, European Urology, vol.67, issue.6
DOI : 10.1016/j.eururo.2014.09.019

Z. S. Zumsteg, Anatomical Patterns of Recurrence Following Biochemical Relapse in the Dose Escalation Era of External Beam Radiotherapy for Prostate Cancer, The Journal of Urology, vol.194, issue.6, pp.1624-1654, 2015.
DOI : 10.1016/j.juro.2015.06.100

P. Rigatti, Pelvic/Retroperitoneal Salvage Lymph Node Dissection for Patients Treated With Radical Prostatectomy With Biochemical Recurrence and Nodal Recurrence Detected by [11C]Choline Positron Emission Tomography/Computed Tomography, European Urology, vol.60, issue.5, pp.935-978, 2011.
DOI : 10.1016/j.eururo.2011.07.060

T. Wiegel, Achieving an Undetectable PSA After Radiotherapy for Biochemical Progression After Radical Prostatectomy Is an Independent Predictor of Biochemical Outcome???Results of a Retrospective Study, International Journal of Radiation Oncology*Biology*Physics, vol.73, issue.4, pp.1009-1025, 2009.
DOI : 10.1016/j.ijrobp.2008.06.1922

E. Daniel and . Soto, Concurrent Androgen Deprivation Therapy During Salvage Prostate Radiotherapy Improves Treatment Outcomes in High-Risk Patients, International Journal of Radiation Oncology ? Biology ? Physics, vol.82, issue.31, pp.1227-1259, 2012.

C. Daher and . Chade, Cancer Control and Functional Outcomes of Salvage Radical Prostatectomy for Radiation-Recurrent Prostate Cancer: A Systematic Review of the Literature', European Urology, vol.61, issue.51, pp.961-71, 2012.

M. Ismail, Salvage cryotherapy for recurrent prostate cancer after radiation failure: a prospective case series of the first 100 patients, BJU International, vol.2, issue.4, pp.760-64, 2007.
DOI : 10.1002/(SICI)1097-0142(19991101)86:9<1793::AID-CNCR22>3.3.CO;2-A

M. Nicole, A. E. Golbari, and . Katz, Salvage Therapy Options for Local Prostate Cancer Recurrence After Primary Radiotherapy: A Literature Review, Current Urology Reports, vol.18, issue.8, pp.63-73, 2017.

V. Helyar, The added value of multislice SPECT/CT in patients with equivocal bony metastasis from carcinoma of the prostate, European Journal of Nuclear Medicine and Molecular Imaging, vol.2, issue.4, pp.706-719, 2010.
DOI : 10.3816/CGC.2003.n.011

W. Römer, SPECT-Guided CT for Evaluating Foci of Increased Bone Metabolism Classified as Indeterminate on SPECT in Cancer Patients, Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine, vol.47, issue.7, pp.1102-1108, 2006.

X. Ndlovu, Should SPECT-CT replace SPECT for the evaluation of equivocal bone scan lesions in patients with underlying malignancies?, Nuclear Medicine Communications, vol.31, issue.7, pp.659-65, 2010.
DOI : 10.1097/MNM.0b013e3283399107

Y. Lin, When to perform bone scintigraphy in patients with newly diagnosed prostate cancer? a retrospective study, BMC Urology, vol.67, issue.2, pp.41-51, 2017.
DOI : 10.1016/j.urology.2005.08.018

S. Loeb, Prostate Specific Antigen at the Initial Diagnosis of Metastasis to Bone in Patients After Radical Prostatectomy, The Journal of Urology, vol.184, issue.1, pp.157-61, 2010.
DOI : 10.1016/j.juro.2010.03.033

M. Beheshti, Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET???CT: a comparative study, European Journal of Nuclear Medicine and Molecular Imaging, vol.33, issue.5, pp.1766-7410, 2008.
DOI : 10.1007/s00259-008-0788-z

R. Kumar and K. , The Role of 18F-Sodium Fluoride PET/CT Bone Scans in the Diagnosis of Metastatic Bone Disease from Breast and Prostate Cancer, Journal of Nuclear Medicine Technology, vol.44, issue.4, pp.217-239, 2016.

U. Tateishi, A meta-analysis of 18F-Fluoride positron emission tomography for assessment of metastatic bone tumor, Annals of Nuclear Medicine, vol.28, issue.7, pp.523-554, 2010.
DOI : 10.1148/radiology.209.1.9769840

. 65-einat-even-sapir, The Detection of Bone Metastases in Patients with High-Risk Prostate Cancer: 99mTc-MDP Planar Bone Scintigraphy, Single-and Multi-Field-of-View SPECT, 18F-Fluoride PET, and 18F-Fluoride PET, Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine, vol.47, issue.2, pp.287-97, 2006.

Q. Zheng, [11C]Choline as a PET biomarker for assessment of prostate cancer tumor models, Bioorganic & Medicinal Chemistry, vol.12, issue.11, pp.2887-93, 2004.
DOI : 10.1016/j.bmc.2004.03.051

S. Balogova, Whole-Body 18F-Fluorocholine (FCH) PET/CT and MRI of the Spine for Monitoring Patients With Castration-Resistant Prostate Cancer Metastatic to Bone, Clinical Nuclear Medicine, vol.39, issue.11, pp.951-59, 2014.
DOI : 10.1097/RLU.0000000000000562

M. Beheshti, F Choline PET/CT in the Preoperative Staging of Prostate Cancer in Patients with Intermediate or High Risk of Extracapsular Disease: A Prospective Study of 130 Patients, Radiology, vol.254, issue.3, pp.925-958, 2010.
DOI : 10.1148/radiol.09090413

F. Ceci, Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial, European Journal of Nuclear Medicine and Molecular Imaging, vol.41, issue.5, pp.2222-3110, 2014.
DOI : 10.1007/s00259-013-2655-9

P. Castellucci, Influence of Trigger PSA and PSA Kinetics on 11C-Choline PET/CT Detection Rate in Patients with Biochemical Relapse after Radical Prostatectomy, Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine, vol.50, issue.9, pp.1394-1400, 2009.

F. Calabria, PET/CT with 18 F???choline: Physiological whole bio-distribution in male and female subjects and diagnostic pitfalls on 1000 prostate cancer patients, Nuclear Medicine and Biology, vol.51, pp.40-54, 2017.
DOI : 10.1016/j.nucmedbio.2017.04.004

P. J. Effert, Metabolic Imaging of Untreated Prostate Cancer by Positron Emission Tomography with sup 18 Fluorine-Labeled Deoxyglucose, The Journal of Urology, vol.155, issue.3, pp.994-98, 1996.
DOI : 10.1016/S0022-5347(01)66366-3

S. D. Yeh, Detection of bony metastases of androgen-independent prostate cancer by PET-FDG, Nuclear Medicine and Biology, vol.23, issue.6, pp.693-97, 1996.
DOI : 10.1016/0969-8051(96)00044-3

H. Jadvar, Is There Use for FDG-PET in Prostate Cancer?', Seminars in Nuclear Medicine, pp.502-508, 2016.

J. Michael and . Morris, Fluorinated Deoxyglucose Positron Emission Tomography Imaging in Progressive Metastatic Prostate Cancer, Urology, vol.59, issue.6, pp.913-931, 2002.

L. Kaliska, Signification d'une hyperfixation prostatique du fluorodésoxyglucose ( 18 F) chez un patient sans antécédent de cancer de la prostate. Cas cliniques, revue et méta-analyse de la littérature, 2014.

J. Jurgen and . Fütterer, Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature, European Urology, vol.68, issue.61, pp.1045-53, 2015.

O. Jelle and . Barentsz, Synopsis of the PI-RADS v2 Guidelines for Multiparametric Prostate Magnetic Resonance Imaging and Recommendations for Use, European Urology, vol.69, issue.11

T. Taoka, Factors Influencing Visualization of Vertebral Metastases on MR Imaging Versus Bone Scintigraphy, American Journal of Roentgenology, vol.176, issue.6, pp.1525-1555, 2001.
DOI : 10.2214/ajr.176.6.1761525

K. Nakanishi, Whole Body MRI for Detecting Metastatic Bone Tumor: Comparison with Bone Scintigrams', Magnetic Resonance in Medical SciencesWhole-Body MRI (WB-MRI) versus Axial Skeleton MRI (AS-MRI) to Detect and Measure Bone Metastases in Prostate Cancer (PCa), MRMS: An Official Journal of Japan Society of Magnetic Resonance in Medicine European Radiology, vol.4, issue.20 12, pp.11-17, 1007.

. Ketelsen, Nachweis oss??rer Metastasen des Prostatakarzinoms ??? Vergleich der Leistungsf??higkeit der Ganzk??rper-MRT und der Skelettszintigrafie, R??Fo - Fortschritte auf dem Gebiet der R??ntgenstrahlen und der bildgebenden Verfahren, vol.180, issue.08, pp.746-5210, 2008.
DOI : 10.1055/s-2008-1027479

G. Shen, Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis, Skeletal Radiology, vol.40, issue.11, pp.1503-1310, 2014.
DOI : 10.1007/s00256-010-0963-8

S. Balogova, Whole-Body 18F-Fluorocholine (FCH) PET/CT and MRI of the Spine for Monitoring Patients With Castration-Resistant Prostate Cancer Metastatic to Bone, Clinical Nuclear Medicine, vol.39, issue.11, pp.951-59, 2001.
DOI : 10.1097/RLU.0000000000000562

R. Luypaert, Diffusion and perfusion MRI: basic physics, European Journal of Radiology, vol.38, issue.1, pp.19-27, 2001.
DOI : 10.1016/S0720-048X(01)00286-8

L. Wu, Diagnostic value of whole-body magnetic resonance imaging for bone metastases: a systematic review and meta-analysis, Journal of Magnetic Resonance Imaging, vol.9, issue.1, pp.128-163, 2011.
DOI : 10.1186/1471-2407-9-18

F. Mosavi, F-NaF PET/CT for Detection of Bone Metastases in Patients With High-Risk Prostate Carcinoma, American Journal of Roentgenology, vol.199, issue.5, pp.1114-1134, 2012.
DOI : 10.2214/AJR.11.8351

I. Jambor, F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial, Acta Oncologica, vol.46, issue.1, pp.59-6710, 2015.
DOI : 10.1111/j.1754-9485.2009.02070.x

E. Frédéric and . Lecouvet, Can Whole-Body Magnetic Resonance Imaging with Diffusion- Weighted Imaging Replace Tc 99m Bone Scanning and Computed Tomography for Single- Step Detection of Metastases in Patients with High-Risk Prostate Cancer, European Urology, vol.62, issue.1, pp.68-75, 2012.

E. Frédéric and . Lecouvet, Whole-Body MR Imaging: Musculoskeletal Applications, pp.345-65, 2016.

M. Beheshti, 18F-NaF PET/CT: EANM procedure guidelines for bone imaging, European Journal of Nuclear Medicine and Molecular Imaging, vol.35, issue.11, pp.1767-7710, 2015.
DOI : 10.1016/S0146-6453(99)00006-8

E. Frédéric, . Lecouvet, J. Vanel, A. Bittoun, and . Tardivon, Whole-Body MR Imaging: Musculoskeletal Applications, European Radiology, vol.279, issue.8 8, pp.345-65, 1998.

G. Shen, Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis, Skeletal Radiology, vol.40, issue.11, pp.1503-1310, 2014.
DOI : 10.1007/s00256-010-0963-8

M. Beheshti, Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET???CT: a comparative study, European Journal of Nuclear Medicine and Molecular Imaging, vol.33, issue.5, pp.1766-7410, 2008.
DOI : 10.1007/s00259-008-0788-z

W. Langsteger, Fluorocholine (18F) and Sodium Fluoride (18F) PET/CT in the Detection of Prostate Cancer: Prospective Comparison of Diagnostic Performance Determined by Masked Reading, The Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol.55, issue.4, pp.448-57, 2011.

P. Cornford, EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer, European Urology, vol.71, issue.4, pp.630-672, 2017.
DOI : 10.1016/j.eururo.2016.08.002

R. Anwar and . Padhani, METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body Magnetic Resonance Imaging-Based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer, European Urology, vol.71, issue.1, pp.81-92, 2017.